IDEXX sold more, kept more of the proceeds, and spent less to build the business during the three months ended June 30. Revenue rose 9.7% to $1.2 billion from the comparable period a year earlier, while gross margin climbed 1.4 percentage points to 64.0%.
That combination pushed operating income up 14.1% to $425.6 million, faster than sales. Diluted earnings per share rose 17.6% to $4.27, helped in part by a 2.1% decline in diluted shares.
The clean version of the filing is a familiar one: volume and pricing are doing the work, and scale is making each sale more profitable. IDEXX said the gross-margin increase came even as inflationary costs continued to press on the business.
"The increase in the gross profit margin was primarily due to lower per-unit costs from higher sales volumes and higher realized prices, which offset inflationary costs."
IDEXX Laboratories, 10-Q, Aug. 4, 2026.
In plain English, the company sold enough to lower its unit costs and charged more, with the two effects outweighing inflation. Gross profit rose 12.1% to $779.1 million, faster than revenue.
The balance sheet adds one unresolved wrinkle. Accounts receivable increased 11.9% to $627.1 million, outpacing revenue growth, while inventory was essentially flat. IDEXX does not say why receivables grew faster than sales. That observation matters because the business can report more profit before all of those sales turn into cash.
The cash figures are not pointing in only one direction. Capital spending fell 11.7%, and free-cash-flow margin improved 6.6 percentage points. Cash was $196.9 million at June 30, up from $164.6 million a year earlier, but the filing also says general and administrative costs rose partly because of bad debt.
"General and administrative expense increased primarily due to higher bad debt costs and higher personnel-related costs."
IDEXX Laboratories, 10-Q, Aug. 4, 2026.
Bad debt is not a forecast, and the filing does not quantify how much of the expense came from that item. It does make the receivables increase harder to ignore: the relationship between receivables and cash is now part of the margin-and-cash conversation, even as inventory and capital spending look contained.
The broader company history gives the current result some continuity. IDEXX's annual revenue reached $4.3 billion in 2025, while operating margin reached 31.6%, up from 21.0% in 2017. The latest period extends that long-running margin expansion rather than introducing a new shape of business.
The market context adds scrutiny to small loose ends. At the latest close, IDEXX had a $46.0 billion market capitalization and traded at 43.4 times earnings. That price does not explain the filing, and the shares rose 1.5% on Aug. 3, but it does make the distinction between profitable growth and cash collected a very visible one.
IDEXX's next quarterly report can put the next accounts-receivable balance and bad-debt expense beside these figures. The question the company has not answered is whether the faster growth in receivables was a one-period accounting wrinkle or a recurring feature of its sales growth.
Source: IDEXX Laboratories' 10-Q filed Aug. 4, 2026, for the three months ended June 30, 2026.